News
Biogen begins phase 3 paediatric study of Omaveloxolone to treat Friedreich ataxia: Cambridge, Mass Saturday, June 21, 2025, 11:00 Hrs [IST] Biogen Inc, a leading biotechnology co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback